Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study
JCO Global Oncology · 2024
DOI: 10.1200/go.23.00461 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Shouki Bazarbashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Frontotemporal Dementia, Phenylurea Compounds, Pyridines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Metastatic colorectal cancer (mCRC) is a significant global health burden. This retrospective study compared the effectiveness of trifluridine/tipiracil (FTD/TPI), regorafenib, and chemotherapy rechallenge for third-line mCRC treatment. MATERIALS AND METHODS We reviewed the medical records of 132 patients with mCRC treated with regorafenib, FTD/TPI, or a rechallenge with the initial chemotherapy regimen in a third-line setting from four different institutions. The primary end point was progression-free survival (PFS). Secondary end points were objective response rate and overall survival (OS) across the three treatment approaches. RESULTS Twenty-nine patients received chemotherapy rechallenge, and 103 received FTD/TPI or regorafenib. Patients' characteristics were comparable, except for a lower number of left-sided primaries and KRAS wild-type tumors in the FTD/TPI-regorafenib group. The median PFS for the entire group was 3.0 months, and the median OS was 13.7 months. Chemotherapy rechallenge has resulted in a median PFS of 3.1 months and a median OS of 21.2 months, compared with 2.9 months (PFS) and 12.6 months (OS) for the FTD/TPI-regorafenib group. Multivariate analyses identified male sex and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 as independent prognostic factors for better PFS, whereas chemotherapy rechallenge, localized stage at diagnosis, and an ECOG PS of 0-1 were significant prognostic factors for better OS. CONCLUSION This study suggests that chemotherapy rechallenge may provide a survival benefit in the third-line treatment of mCRC. However, patient characteristics, such as sex and ECOG PS, should also be considered in treatment decisions. Further prospective studies are required to confirm our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
- Faculty of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- Department of Internal Medicine, Section of Medical Oncology, Security Forces Hospital, Riyadh, Saudi Arabia.
- Department of Medical Oncology, King Saud University Medical City, King Saud University, National Blood and Cancer Centre, Riyadh, Saudi Arabia.
- Oncology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
- Faculty of Medicine, Minia University, Minia, Egypt.
ORCID-Profile: Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, Mervat Mahrous, Sherif Elsamany, Mohammed Alghamdi
Zitieren
APA
Bazarbashi, S., Alkhatib, R., Aseafan, M., Tuleimat, Y., Abdel-Aziz, N., Mahrous, M., Elsamany, S., Elhassan, T., & Alghamdi, M. (2024). Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO Global Oncology. https://doi.org/10.1200/go.23.00461
Vancouver
Bazarbashi S, Alkhatib R, Aseafan M, Tuleimat Y, Abdel-Aziz N, Mahrous M, et al. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO Global Oncology. 2024. doi:10.1200/go.23.00461
BibTeX
@article{Bazarbashi2024,
author = {Bazarbashi, Shouki and Alkhatib, Radwan and Aseafan, Mohamed and Tuleimat, Yasmin and Abdel-Aziz, Nashwa and Mahrous, Mervat and Elsamany, Sherif and Elhassan, Tusneem and Alghamdi, Mohammed},
title = {Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go.23.00461}
}
EUVIMED